clopidogrel (Plavix)
Jump to navigation
Jump to search
[1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32][33][34][35][36][37][38][39][40][41][42][43][44][45][46][47][48]
Introduction
Tradename: Plavix. Clopidogrel bisulfate. Generic May 2012[33]
Indications
- aspirin failure
- stroke prophylaxis*
- prevention of arterial thromboembolism
- percutaneous coronary intervention (PCI) & s/p coronary stent (see CHARISMA trial)
- antiplatelet prophylaxis prior to PTCA for STEMI[12]
- post myocardial infarction (see COMMIT trial)
- secondary prevention in patients with cardiovascular disease
- patients with diabetes mellitus benefit less[36]
- unstable angina (in combination with aspirin)#
- cardiovascular risk reduction
* addition of aspirin NOT superior to clopidogrel alone[8] (see MATCH study)
# increased risk of bleeding offset by lower mortality from cardiovascular events[4], see CHARISMA trial
Contraindications
- hemorrhagic disorder (GI bleed, hemorrhagic stroke ...)
- cardiovascular risk reduction (in combination with aspirin) (see CHARISMA trial)
Benefit/risk
- secondary prevention of cardiovascular events[44]
- number needed to treat (NNT)
- 50 for 1 year to prevent 1 cardiovascular event
- number needed to treat (NNT)
- in combination with aspirin
- for 1 year following coronary stent
- no mortality benefit[43]
- number needed to treat (NNT) to prevent 1 non-fatal MI or 1 stroke = 27[43]
- number need to harm (major hemorrhage) = 117
- no benefit when added to aspirin for secondary prevention of cardiovascular events[45]
- for 1 year following coronary stent
- percutaneous coronary intervention (PCI)
- number needed to harm: 275 to result in 1 serious hemorrhage[46]
Dosage
- 75 mg PO QD
- use in combination with aspirin 81 mg QD for coronary artery disease may be of benefit
- stop Plavix 5-7 days prior to elective surgery
- 600 mg once prior to percutaneous intervention (PCI),followed by 150 mg QD for 6 days, then 75 mg QD in combination with 81 mg aspirin[22]
- 2/3 of clopidogrel non-responders will respond to 150 mg/day[19]
Tabs: 75 mg
Pharmacokinetics
- rapidly absorbed after oral administration
- absorbtion unaffected by food
- activation dependent upon CYP3A4 & CYP2C19;
- reduced function CYP2C19 alleles inadequately activate clopidogrel & are associated with worse clinical outcomes[18]
- CYP2C19*1 allele fully functional metabolism of clopidogrel
- CYP2C19*2 & CYP2C19*3 alleles have no functional metabolism of clopidogrel*
- CYP2C19*4, *5, *6, *7, & *8 & other alleles may be associated with absent or reduced metabolism of clopidogrel, but are less frequent than CYP2C19*2 & CYP2C19*3 alleles
- a patient with two loss-of-function alleles will have poor metabolizer status
- cyt P450 2B metabolizes clopidogrel to inactive metabolites
- steady state activity takes 3-7 days
- once stopped, it takes 5 days for anti-platelet activity to stop
- 600 mg achieves maximum platelet inhibition in 2 hours
* ticagrelor & pasugrel not activated by CYP2C19
elimination via kidney
elimination via liver
1/2life = 8 hours
Monitor
- CYP2C19 allele testing (research, see Pharmacokinetics)
- clinical utility of CYP2C19 genotyping uncertain[31][32]
Adverse effects
- overall tolerability is similar to aspirin
- 13% of patients will experience adverse effects sufficient to withdraw therapy
- neutropenia 0.8%
- gastrointestinal 27%
- abdominal pain
- dyspepsia
- gastritis & upper GI bleeding[11]
- proton pump inhibitor may reduce risk[16][29]
- esomeprazole more effective than famotidine in preventing GI bleed when clopidogrel is used in combination with aspirin[34]
- although not a primary cause of gastroduodenal ulcers, may impair healing of existing ulcers & erosions by inhibiting angiogenesis
- 150 mg QD may increase risk relative to 75 mg QD[38]
- constipation
- diarrhea
- dermatologic 16% (higher than aspirin)
- rash
- pruritus
- 1.5% severe enough for withdrawal of therapy
- hemorrhage
- headache
- chest pain
- dizziness
- thrombotic thrombocytopenic purpura (TTP) (0.001-0.006%)[10]
- increased risk of major bleeding if given within 5 days of CABG[20];
- discontinue clopidogrel & postpone surgery if feasible[20]
- increased risk of severe postoperative wound complications after cutaneous surgery (3% vs 0.5% for aspirin)[30]
- long-term treatment with clopidogrel does not increase or decrease overall risk of mortality in patients with or at risk for heart disease[48]
- drug adverse effects of antiplatelet agents
- drug adverse effects of antithrombotic agent(s)
- drug adverse effects of P2Y12 receptor inhibitor(s)
Drug interactions
- in vitro, high concentrations of clopidogrel inhibit cytochrome P450 2C9
- clopidogrel may potentially interfere with metabolism of:
- administration with heparin has not been studied
- drugs that inhibit CYP3A4 & CYP2C19 may inhibit activation of clopidogrel & diminish antiplatelet effect
- proton pump inhibitors[22][25]
- omeprazole > rabeprazole, pantoprazole, lansoprazole;
- prasugrel may have less interaction with PPIs[24]
- omeprazole may cut the effect of clopidogrel in half[26]
- interaction of clopidogrel with proton pump inhibitors "clinically unimportant"[35]
- no increase in risk for adverse cardiovascular events with addition of a PPI to a clopidogrel[47]
- other CYP2C19 inhibitors not recommended for use with clopidogrel
- proton pump inhibitors[22][25]
- No significant interactions of clopidogrel with statins
- increased risk of serious bleeding when used in combination with aspirin 81 mg QD[8]
- smoking induces CYP 3A4 that converts clopidogrel into its active metabolite thus enhances platelet inhibition by clopidogrel[15][21]
- drug interaction(s) of anti-platelet agents with SSRIs
- drug interaction(s) of aspirin, clopidogrel & warfarin
- drug interaction(s) of antiplatelet agents with proton pump inhibitors
- drug interaction(s) of clopidogrel with proton pump inhibitors
- drug interaction(s) of warfarin with antiplatelet agents
- drug interaction(s) of aspirin, P2Y12 inhibitors & anticoagulants
Mechanism of action
- inhibits platelet aggregation by irreversibly binding the platelet ADP receptor
- biotransformation of Clopidogrel is necessary for anti-platelet activity, but the active metabolite is unknown
- prolongs bleeding time
- 40-100 times more potent than ticlopidine
- reduces vascular smooth muscle contraction
- prevents reocclusion rather than facilitates early reperfusion after fibrinolysis[13]
- impairs angiogenesis
Notes
cost $110/month in US (2001), $150/month (2009)
More general terms
Additional terms
References
- ↑ Lancet 348:9038
- ↑ Bristol-Myers Squibb package insert
- ↑ Drug Information & Medication Formulary, Veterans Affairs, Central California Health Care System, 1st ed., Ravnan et al eds, 1998
- ↑ 4.0 4.1 Prescriber's Letter 8(4):20 2001 Clopidogrel In The Treatment Of Acute Coronary Syndromes Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=170422&pb=PRL (subscription needed) http://www.prescribersletter.com
- ↑ Prescriber's Letter 9(4):20 2002
- ↑ 6.0 6.1 Prescriber's Letter 10(1):1 2003
- ↑ 7.0 7.1 Journal Watch 23(20):161, 2003 Saw J et al, Circulation 108(Aug 26):921, 2003 PMID: https://www.ncbi.nlm.nih.gov/pubmed/12925453
- ↑ 8.0 8.1 8.2 Journal Watch 24(17):133, 2004 Diener HC, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, Kaste M, Leys D, Matias-Guiu J, Rupprecht HJ; MATCH investigators. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo- controlled trial. Lancet. 2004 Jul 24;364(9431):331-7. PMID: https://www.ncbi.nlm.nih.gov/pubmed/15276392
- ↑ Prescriber's Letter 11(10): 2004 Concomitant use of Aspirin and Clopidogrel (Plavix) in Cerebrovascular Disease Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=201002&pb=PRL (subscription needed) http://www.prescribersletter.com
- ↑ 10.0 10.1 Ovbiagele B, In: Intensive Course in Geriatric Medicine & Board Review, Marina Del Ray, CA, Sept 29-Oct 2, 2004
- ↑ 11.0 11.1 Prescriber's Letter 12(3): 2005 Safety of Clopidogrel (Plavix) in Patients at Risk for Ulcers Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=210304&pb=PRL (subscription needed) http://www.prescribersletter.com
Journal Watch 25(4):29, 2005 Chan FK, Ching JY, Hung LC, Wong VW, Leung VK, Kung NN, Hui AJ, Wu JC, Leung WK, Lee VW, Lee KK, Lee YT, Lau JY, To KF, Chan HL, Chung SC, Sung JJ. Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N Engl J Med. 2005 Jan 20;352(3):238-44. PMID: https://www.ncbi.nlm.nih.gov/pubmed/15659723
Cryer B. Reducing the risks of gastrointestinal bleeding with antiplatelet therapies. N Engl J Med. 2005 Jan 20;352(3):287-9. No abstract available. PMID: https://www.ncbi.nlm.nih.gov/pubmed/15659730 - ↑ 12.0 12.1 Sabatine MS, Cannon CP, Gibson CM, Lopez-Sendon JL, Montalescot G, Theroux P, Lewis BS, Murphy SA, McCabe CH, Braunwald E; Clopidogrel as Adjunctive Reperfusion Therapy (CLARITY)-Thrombolysis in Myocardial Infarction (TIMI) 28 Investigators. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. JAMA. 2005 Sep 14;294(10):1224-32. Epub 2005 Sep 4. PMID: https://www.ncbi.nlm.nih.gov/pubmed/16143698
- ↑ 13.0 13.1 Scirica BM et al, The role clopidogrel in early and sustained arterial patency after fibrinolysis for ST segment elevation myocardial infarction The ECG CLARITY-TIMI 29 Study J Am Coll Cardiol 2006, 48:37 PMID: https://www.ncbi.nlm.nih.gov/pubmed/16814646
- ↑ Prescriber's Letter 15(3): 2008 Is abrupt discontinuation of Plavix (Clopidogrel) Safe? Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=240305&pb=PRL (subscription needed) http://www.prescribersletter.com
Ho PM et al, Indidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome. JAMA 2008, 299:532 PMID: https://www.ncbi.nlm.nih.gov/pubmed/18252883 - ↑ 15.0 15.1 Bliden KP et al. The association of cigarette smoking with enhanced platelet inhibition by clopidogrel. J Am Coll Cardiol 2008 Aug 12; 52:531. PMID: https://www.ncbi.nlm.nih.gov/pubmed/18687246
- ↑ 16.0 16.1 Prescriber's Letter 15(21): 2008 Reducing the Risk for GI Bleeding with Antiplatelet Drugs Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=241205&pb=PRL (subscription needed) http://www.prescribersletter.com
- ↑ Bhatt DL et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Am J Gastroenterol 2008 Nov; 103:2890.
Bhatt DL et al, ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol. 2008 Oct 28;52(18):1502-17. PMID: https://www.ncbi.nlm.nih.gov/pubmed/19017521
Bhatt DL et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation 2008 Oct 28; 118:1894. PMID: https://www.ncbi.nlm.nih.gov/pubmed/18836135 - ↑ 18.0 18.1 Mega JL et al Cytochrome P-450 polymorphisms and response to clopidogrel. N Engl J Med 2008 Dec 22; [e-pub ahead of print] <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/19106084 <Internet> http://dx.doi.org/10.1056/NEJMoa0809171
Simon T et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2008 Dec 22; [e-pub ahead of print] <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/19106083 <Internet> http://dx.doi.org/10.1056/NEJMoa0808227
Collet JP et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: A cohort study. Lancet 2008 Dec 23; [e-pub ahead of print]. <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/19108880 <Internet> http://dx.doi.org/10.1016/S0140-6736(08)61845-0 - ↑ 19.0 19.1 Aleil B et al Clopidogrel 150 mg/day to overcome low responsiveness in patients undergoing elective percutaneous coronary intervention: Results from the VASP-02 (vasodilator- stimulated phosphoprotein-02) randomized study. J Am Coll Cardiol Intv 2008 Dec; 1:631 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/19463377 <Internet> http://interventions.onlinejacc.org/cgi/content/full/1/6/631
Cuisset T et al Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: A prospective, randomized study. J Am Coll Cardiol Intv 2008 Dec; 1:649 http://interventions.onlinejacc.org/cgi/content/full/1/6/649
Bhatt DL Resisting the temptation to oversimplify antiplatelet resistance. J Am Coll Cardiol Intv 2008 Dec; 1:660 http://interventions.onlinejacc.org/cgi/content/full/1/6/660 - ↑ 20.0 20.1 20.2 Berger JS et al Impact of clopidogrel in patients with acute coronary syndromes requiring coronary artery bypass surgery: A multicenter analysis. J Am Coll Cardiol 2008 Nov 18; 52:1693. PMID: https://www.ncbi.nlm.nih.gov/pubmed/19007688
- ↑ 21.0 21.1 Desai NR et al. Interaction between cigarette smoking and clinical benefit of clopidogrel. J Am Coll Cardiol 2009 Apr 14; 53:1273. PMID: https://www.ncbi.nlm.nih.gov/pubmed/19358940
- ↑ 22.0 22.1 22.2 Prescriber's Letter 16(7): 2009 Proton Pump Inhibitor and Plavix Interaction: An Update Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=250706&pb=PRL (subscription needed) http://www.prescribersletter.com
Prescriber's Letter 16(11): 2009 Proton Pump Inhibitor and Plavix Interaction: An Update Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=251107&pb=PRL (subscription needed) http://www.prescribersletter.com - ↑ Prescriber's Letter 16(10): 2009 The Case for a Higher Maintenance Dose of Clopidogrel (Plavix) Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=251004&pb=PRL (subscription needed) http://www.prescribersletter.com
- ↑ 24.0 24.1 O'Donoghue ML et al Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: An analysis of two randomised trials. Lancet 2009 Sep 19; 374:989. PMID: https://www.ncbi.nlm.nih.gov/pubmed/19726078
- ↑ 25.0 25.1 25.2 FDA MedWatch, Posted 11/17/2009 Clopidogrel (marketed as Plavix) and Omeprazole (marketed as Prilosec) - Drug Interaction http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm190848.htm
- ↑ 26.0 26.1 FDA Alert, 11/17/2009 Information for Healthcare Professionals: Update to the labeling of Clopidogrel Bisulfate (marketed as Plavix) to alert healthcare professionals about a drug interaction with omeprazole (marketed as Prilosec and Prilosec OTC) http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm190787.htm
- ↑ Prescriber's Letter 17(1): 2010 Cytochrome P450 Drug Interactions CHART: Cytochrome P450 Drug Interactions COMMENTARY: Proton Pump Inhibitor and Plavix Interaction: An Update Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=260112&pb=PRL (subscription needed) http://www.prescribersletter.com
- ↑ FDA Medwatch Plavix (clopidogrel): Reduced effectiveness in patients who are poor metabolizers of the drug http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm204256.htm
- ↑ 29.0 29.1 Hsu P-I et al. Esomeprazole with clopidogrel reduces peptic ulcer recurrence, compared with clopidogrel alone, in patients with atherosclerosis. Gastroenterology 2011 Mar; 140:791. PMID: https://www.ncbi.nlm.nih.gov/pubmed/21144850
- ↑ 30.0 30.1 Cook-Norris RH et al. Complications of cutaneous surgery in patients taking clopidogrel-containing anticoagulation. J Am Acad Dermatol 2011 Apr 22 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/21514003 <Internet> http://www.sciencedirect.com/science/article/pii/S0190962211002386
- ↑ 31.0 31.1 Bauer T et al. Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: Systematic review and meta-analysis. BMJ 2011 Aug 4; 343:d4588 PMID: https://www.ncbi.nlm.nih.gov/pubmed/21816733
- ↑ 32.0 32.1 Holmes MV et al. CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: A systematic review and meta-analysis. JAMA 2011 Dec 28; 306:2704. PMID: https://www.ncbi.nlm.nih.gov/pubmed/22203539
Nissen SE. Pharmacogenomics and clopidogrel: Irrational exuberance? JAMA 2011 Dec 28; 306:2727. PMID: https://www.ncbi.nlm.nih.gov/pubmed/22203545 - ↑ 33.0 33.1 Prescriber's Letter 19(4): 2012 CHART: Anticipated Availability of First-Time Generics Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=280401&pb=PRL (subscription needed) http://www.prescribersletter.com
FDA News Release: May 17, 2012 FDA approves generic versions of blood thinner Plavix http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm304489.htm - ↑ 34.0 34.1 Ng F-H et al. Esomeprazole compared with famotidine in the prevention of upper gastrointestinal bleeding in patients with acute coronary syndrome or myocardial infarction. Am J Gastroenterol 2012 Mar; 107:389. PMID: https://www.ncbi.nlm.nih.gov/pubmed/22108447
- ↑ 35.0 35.1 Douglas IJ et al Clopidogrel and interaction with proton pump inhibitors: comparison between cohort and within person study designs. BMJ 2012;345:e4388 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/22782731 <Internet> http://www.bmj.com/content/345/bmj.e4388
Targownik LE Prescribing proton pump inhibitors with clopidogrel BMJ 2012;345:e4558 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/22782732 <Internet> http://www.bmj.com/content/345/bmj.e4558 - ↑ 36.0 36.1 Andersson C et al Association of Clopidogrel Treatment With Risk of Mortality and Cardiovascular Events Following Myocardial Infarction in Patients With and Without Diabetes. JAMA. 2012;308(9):882-889 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/22948698 <Internet> http://jama.jamanetwork.com/article.aspx?articleid=1356353
Bhatt DL Antiplatelet Therapy Following Myocardial Infarction in Patients With Diabetes JAMA. 2012;308(9):921-922 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/22948703 <Internet> http://jama.jamanetwork.com/article.aspx?articleid=1356337 - ↑ 37.0 37.1 Gagne JJ et al Effect of smoking on comparative efficacy of antiplatelet agents: systematic review, meta-analysis, and indirect comparison. BMJ 2013;347:f5307 http://www.bmj.com/content/347/bmj.f5307
- ↑ 38.0 38.1 Lin CC et al Risk factors of gastrointestinal bleeding in clopidogrel users: A nationwide population-based study. Aliment Pharmacol Ther 2013 Nov; 38:1119 PMID: https://www.ncbi.nlm.nih.gov/pubmed/24099473
- ↑ Deprecated Reference
- ↑ Bates ER, Lau WC, Angiolillo DJ. Clopidogrel-drug interactions. J Am Coll Cardiol. 2011 Mar 15;57(11):1251-63. Review. PMID: https://www.ncbi.nlm.nih.gov/pubmed/21392639
- ↑ Cuisset T, Frere C, Quilici J et al Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose the PACA (Proton Pump Inhibitors And Clopidogrel Association) prospective randomized study. J Am Coll Cardiol. 2009 Sep 22;54(13):1149-53. PMID: https://www.ncbi.nlm.nih.gov/pubmed/19761935
- ↑ Kreutz RP, Stanek EJ, Aubert R et al Impact of proton pump inhibitors on the effectiveness of clopidogrel after coronary stent placement: the clopidogrel Medco outcomes study. Pharmacotherapy. 2010 Aug;30(8):787-96 PMID: https://www.ncbi.nlm.nih.gov/pubmed/20653354
- ↑ 43.0 43.1 43.2 The NNT: Clopidogrel Added To Aspirin During and After a Coronary Event or a Stent Procedure. http://www.thennt.com/nnt/clopidogrel-added-to-aspirin-during-and-after-a-coronary-event-or-stenting/
- ↑ 44.0 44.1 44.2 The NNT: Clopidogrel to Prevent Cardiovascular Disease for People Who Have Had Heart Attacks or Strokes. http://www.thennt.com/nnt/clopidogrel-for-cardiovascular-prevention-after-prior-heart-attack-or-stroke/
- ↑ 45.0 45.1 The NNT: Clopidogrel Added to Aspirin to Prevent a Second Heart Attack Or Stroke. http://www.thennt.com/nnt/clopidogrel-with-aspirin-for-prevention-after-prior-heart-attack-or-stroke/
Squizzato A, Keller T, Romualdi E, Middeldorp S Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular disease. Cochrane Database Syst Rev. 2011 Jan 19;(1):CD005158 PMID: https://www.ncbi.nlm.nih.gov/pubmed/21249668
Bowry AD, Brookhart MA, Choudhry NK. Meta-analysis of the efficacy and safety of clopidogrel plus aspirin as compared to antiplatelet monotherapy for the prevention of vascular events. Am J Cardiol. 2008 Apr 1;101(7):960-6 PMID: https://www.ncbi.nlm.nih.gov/pubmed/18359315 - ↑ 46.0 46.1 FDA News Release. June 22, 2015 FDA approves new antiplatelet drug used during heart procedure. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm452172.htm
- ↑ 47.0 47.1 Cardoso RN et al. Incidence of cardiovascular events and gastrointestinal bleeding in patients receiving clopidogrel with and without proton pump inhibitors: An updated meta-analysis. Open Heart 2015; 2:e000248 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/26196021 <Internet> http://openheart.bmj.com/content/2/1/e000248
- ↑ 48.0 48.1 FDA Safety Alert. Nov 6, 2015 Plavix (clopidogrel): Drug Safety Communication - Long-term Treatment Does Not Change Risk of Death. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm471531.htm
FDA Drug Safety Communication. Nov 6, 2015 FDA review finds long-term treatment with blood-thinning medicine Plavix (clopidogrel) does not change risk of death. http://www.fda.gov/Drugs/DrugSafety/ucm471286.htm